Tri-coordinate Au(I) Probes for Mitochondrial Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective tools to selectively disrupt mitochondrial structure in cancer cells while sparing normal epithelial cells, and there is a need for gold-based agents that can interact specifically with mitochondrial oxidative phosphorylation machinery.
Innovation Solution
Development of tri-coordinate Au(I) complexes with diverse NAN-bidentate ligands and monodentate arsine or phosphine ancillary ligands to create compounds that selectively target and disrupt mitochondrial structure in cancer cells, using their unique geometry and reactivity to interact with biomolecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gold compounds are used to target mitochondria, then mitochondrial interaction is achieved, but selective disruption of mitochondrial structure in cancer cells versus normal epithelial cells is not accomplished
Solution Approach 1:
The patent applies local quality by creating gold compounds with specific geometric configurations (linear vs. trigonal bipyramidal) that selectively interact with mitochondrial structures in cancer cells. The unique geometry of the gold compounds allows them to target specific mitochondrial components such as oxidative phosphorylation machinery, achieving localized disruption in cancer cells while sparing normal epithelial cells, thus resolving the contradiction between mitochondrial targeting and selective disruption.
Solution Approach 2:
The patent utilizes asymmetry by designing gold compounds with asymmetric geometric configurations. The trigonal bipyramidal geometry of the gold compounds creates asymmetric interaction patterns with mitochondrial proteins, enabling selective disruption of mitochondrial structure in cancer cells. This asymmetric approach allows the gold compounds to distinguish between cancer cell mitochondria and normal cell mitochondria, reducing toxicity to normal cells while maintaining therapeutic efficacy.
2Reliability
If existing gold-based therapies are used, then some therapeutic activity is achieved, but effective tools to selectively disrupt mitochondrial structure are not available
Solution Approach 1:
The patent applies parameter changes by systematically varying the geometric parameters of gold compounds (coordination number, bond angles, ligand types) to optimize mitochondrial disruption activity. By changing these structural parameters, the gold compounds achieve effective therapeutic activity while developing the specific adaptability needed to target mitochondrial structure. This parameter optimization resolves the contradiction between general therapeutic activity and specific mitochondrial disruption capability.
3Reliability
If tri-coordinate Au(I) complexes are developed with unique geometry, then selective mitochondrial interaction is achieved, but complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the gold compound design into modular components: a central gold center with specific coordination geometry, bidentate ligands (such as phenanthroline derivatives), and monodentate ligands (such as phosphines or arsines). This modular segmentation allows systematic variation of individual components to optimize mitochondrial selectivity while maintaining manageable synthesis complexity. The segmented approach resolves the contradiction between achieving unique geometric configurations and managing design complexity.
Data Source
AI summary
The presently-disclosed subject matter tri-coordinate Au(I) complexes, and methods of using tri-coordinate Au(I) complexes for selectively disrupting mitochondrial structure of target cancer cells.